Actively Recruiting
Stockholm Myocardial Infarction with Nonobstructive Coronaries Study 3
Led by Karolinska Institutet · Updated on 2025-03-10
85
Participants Needed
1
Research Sites
191 weeks
Total Duration
On this page
Sponsors
K
Karolinska Institutet
Lead Sponsor
R
Region Stockholm
Collaborating Sponsor
AI-Summary
What this Trial Is About
The present pilot study will investigate the prevalence of CMD in an unselected cohort of patients with the working diagnosis MINOCA and to study if the diagnostic yield can be improved by adding adenosine to the CMR investigation. Patient will be their own controls.
CONDITIONS
Official Title
Stockholm Myocardial Infarction with Nonobstructive Coronaries Study 3
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Suspected diagnosis of MINOCA or takotsubo syndrome with coronary angiography showing no diameter stenosis ≥50%
- Age between 35 and 80 years
- Ability to read and write Swedish
You will not qualify if you...
- Claustrophobia
- Presence of arrhythmia or pacemaker, including atrial fibrillation and AV-block I-III
- Asthma or severe chronic obstructive lung disease
- Estimated glomerular filtration rate (eGFR) less than 30 ml/min
- Spontaneous coronary artery dissection
- Acute pulmonary embolism
- Acute myocardial infarction type 2
- Cardiomyopathy other than takotsubo syndrome
- Previous myocardial infarction due to coronary artery disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Per Tornvall
Stockholm, Sweden, 11551
Actively Recruiting
Research Team
P
Per Tornvall, MD
CONTACT
P
Peder Sörensson, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here